Transcriptional readthrough progresses from incidental byproduct to therapeutic opportunity

Agata Stępień; Martyna Plens-Gałąska; Kinga Kamieniarz-Gdula

doi:10.1038/s41594-026-01833-4

June 30, 2026Nature Structural & Molecular BiologyOpen Access

Transcriptional readthrough progresses from incidental byproduct to therapeutic opportunity

View Full Paper

Ask AI

Bookmark

Share

Key Points

To explore the shift of transcriptional readthrough from being seen as an incidental byproduct to a potential therapeutic avenue.
Review of existing literature on transcriptional readthrough and its implications in cancer treatment.
Transcriptional readthrough can trigger beneficial effects in oncological contexts.
Recent studies show functional roles for readthrough beyond mere byproducts.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Transcriptional readthrough is functional and may provide new therapeutic options in cancer treatment, suggesting exciting possibilities.

Abstract

Several anti-cancer drugs delay transcription termination, triggering transcriptional readthrough. Readthrough has long been considered an incidental transcriptional byproduct, however a recent study reveals that it can be functional and might even offer a therapeutic opportunity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stępień et al. (2026) studied this question.

synapsesocial.com/papers/6a4600c99ed1343031310cb3 https://doi.org/10.1038/s41594-026-01833-4

View Full Paper

Ask AI

Bookmark

Share

Transcriptional readthrough progresses from incidental byproduct to therapeutic opportunity

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Transcriptional readthrough progresses from incidental byproduct to therapeutic opportunity

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading